

✓ecancer is a charity with a mission to raise the standards of care for cancer patients across the world through education. #openaccess


Men get your #PSA test for #prostatecancer! A new screening guideline update today from @americancancer researchers led by Dr. Robert Smith & @billdahutmd in @CACancerJournal recommends PSA testing starting at 50 for men at average risk. Read more here: pressroom.cancer.org/prostat…

Can AI help predict breast cancer recurrence risk? 🤔 New research suggests it may have an important role. In a recent @ecancer interview, Dr. Laura van 't Veer (@LVVPrint) discusses an investigational AI-based digital MammaPrint assay that demonstrated a strong correlation (r = 0.954) between risk scores generated from digital pathology images and those from the established 70-gene MammaPrint assay. 🎥 Learn more: agendia.com/ai-based-digital… #BreastCancerResearch #PrecisionOncology #MammaPrint #ESMO26

Do you know that the @ecancer #ESMO26 highlights video are separated by tumor types and are time stamped so that you can just select the tumor type and trials you want to listen to? These are the breast cancer trials, for example. ecancer.org/en/video/13116-e…

Join us on 16 November at 17:00 GMT/18:00 CET for a free, interactive webinar on the latest in #bladdercancer. Explore new research and clinical insights. Register 👉ecancer.org/bladder #ESMO26 #EMUC26 @AlisonBirtle @nachoduranm @amerseburger @MRoupret

My annual tradition of @ecancer ESMO highlights video continues! Watch this video for an unbiased commentary on the most important trials and news coming out of #ESMO26. ecancer.org/en/video/13116-e…

sac-TMT reduced the risk of disease progression or death by 41% and the risk of death by 32% vs chemo in advanced or recurrent endometrial cancer. Watch @BPothuri discuss TroFuse-005 trial👉 ow.ly/szAO51016ck #ESMO26 #EndometrialCancer #CancerResearch

Thank you everyone who attended our proffered paper policy session yesterday. Thankful to the scientific session for selecting our abstract for oral. Thank you to the chairs and discussants for creating this fantastic session and for putting our results into context. @myESMO #ESMO26

#ESMO26: Risvutatug rezetecan improves PFS in relapsed/refractory osteosarcoma. Dr Lu Xie discusses the findings with ecancer. Watch here: ecancer.org/en/video/13120-r… #oncology #Osteosarcoma #OncologyResearch @PKU1898

Pembrolizumab monotherapy improves PFSl and QoL in advanced or recurrent dMMR endometrial cancer. Watch Dr Brian Slomovitz discuss his study👉ow.ly/oE9h51013wG #EndometrialCancer #ESMO26 #CancerResearch @GynCancerMD

Interim MOIO trial reveals routine de-escalation of checkpoint inhibitors based solely on initial response is not supported by prospective data. Watch Dr Gwenaëlle Gravis discuss the trial 👉ow.ly/Vps151013pW @paoli_calmettes #ESMO26

Oral abstract #BreastCancer session at #ESMO26: phase II data on addition of #tucatinib to the ongoing anti-HER2 therapy in patients with advanced #HER2+ disease with brain-only relapse @OncoAlert @myESMO

#ESMO26 nice summary by Antonio Llombart on CNS studies in mHER2 positive disease! Congrats to all. @OncoAlert

Oral abstract #BreastCancer session at #ESMO26: prospective data on ADC sequencing showing very limited activity with the second ADC by only changing the target @OncoAlert @myESMO

AZUR-1: Dostarlimab alone achieved 68% sustained complete response at 12 months in dMMR/MSI-H locally advanced rectal cancer. Could IO spare patients chemo, radiotherapy & surgery? Watch here👉ow.ly/wqVQ5100Vg6 @MeredithPelster @SCRIOncology #ESMO26 #RectalCancer

Intismeran autogene + pembrolizumab reduces the risk of recurrence or death by 42% in resected stage IIB–IV melanoma, improving recurrence-free survival vs pembrolizumab alone. Watch @ProfGLongMIA speak to ecancer👉bit.ly/4zQGGtc #ESMO26